AI training is  driving HPC advances in drug...

The climate in which R&D teams are operating today is competitive, to say the least. 

The breakneck pace at which innovation must move in its earliest of stages creates a battleground within the research landscape, one where data is the best weapon against the invisible enemies science aims to destroy, and technology provides the differentiating high-ground from which the fight can be won. 

The sprint toward early discovery is one of the most important legs in the long, expensive, and compliance-driven relay race to bring new drugs or treatments to market. Not only does being first to market with medical innovation provide companies with the opportunity to patent and sell a new treatment as the sole distributor, the reputational value associated with doing so can also be almost immeasurable.